Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people notice semaglutide starting to work within the first week or two, though the timeline varies. The medicine begins reducing appetite and slowing gastric emptying from the first dose, but meaningful, sustained weight loss builds over months — not days. As a prescription-only medicine, it must be started under clinical supervision. Here is what the evidence actually shows, week by week.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide begins binding to GLP-1 receptors from the moment it enters your bloodstream. In the first few days after your first 0.25 mg injection, the most common experience is not dramatic hunger reduction but rather mild gastrointestinal changes: some nausea, a slight shift in how quickly you feel full, or a change in semaglutide's effect on bowel movements. These are early signs the medicine is pharmacologically active.
What you are unlikely to feel in week one is a pronounced drop in appetite. The starting dose is specifically designed to ease your system into the medicine, its primary job is tolerability, not full therapeutic effect. The semaglutide overview on our site explains the mechanism in more detail, but the short version is that 0.25 mg is a calibration phase. Hunger may dip slightly. Weight on the scale may not shift at all. That is normal and expected.
A practical note: many people inject on the same day each week, first thing in the morning, keeping the pen in the fridge door alongside everyday items rather than storing it somewhere easy to forget. A consistent routine matters more at this stage than anything else.
By the second and third week, most people report a more consistent reduction in hunger between meals. Portion sizes feel more manageable. The urge to snack diminishes. These changes happen gradually rather than suddenly, which is why the question of how many days it takes rarely has a single clean answer.
The dose titration schedule (moving from 0.25 mg to 0.5 mg, then upward toward 1.0 mg, 1.7 mg and ultimately 2.4 mg, roughly every four weeks under prescriber guidance) is directly tied to how strongly the effects are felt. As the dose increases, so does receptor activation and appetite suppression. Many people find each step-up brings a noticeable shift in how much they want to eat.
Weight loss during this phase is real but modest. The scale may move by one to three kilograms over the first month. That modest early figure is not a sign the medicine is not working; it reflects the staged nature of the titration. The detailed breakdown of when Wegovy starts working covers this progression across the full dose schedule.
Once at or near the maintenance dose of 2.4 mg (or the newer 7.2 mg option, approved by the MHRA in January 2026 for eligible patients), the full appetite-suppressing and metabolic effects of semaglutide are active. This is when the trial data becomes most relevant.
The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity over 68 weeks and reported an average weight reduction of around 15% at the 2.4 mg weekly dose, alongside lifestyle changes. That outcome was not achieved by month two; it accumulated steadily over more than a year. Weight loss is rarely linear, it plateaus, restarts and shifts pace. Treating the first few weeks as a settling-in period rather than a verdict on whether the medicine works is a more accurate framing.
People often ask whether a missed dose resets the timeline. The short answer is: a single late or missed injection has a limited effect if managed correctly, and our page on how many days you can miss Wegovy covers that scenario in full. The key is not to double up doses, always check the patient information leaflet and speak to your prescriber.
Individual variation is real. Factors including starting weight, dietary habits, activity levels, metabolic rate and how your body tolerates the titration all affect how quickly (and how strongly) you feel semaglutide's effects. Clinical trials report averages across hundreds or thousands of participants; your own trajectory may lead or lag that average. The NHS semaglutide medicines page notes that results vary and that the medicine works best alongside a reduced-calorie diet and increased physical activity.
If appetite suppression feels weak even after several months on the maintenance dose, that is worth discussing with your prescriber rather than assuming treatment has failed. Dose adjustments, dietary protein adequacy, hydration and the timing of meals all interact with how effective the medicine feels day to day. Questions like when Wegovy starts working for different people are ones our clinical team fields regularly.
Thinking about starting treatment? For those considering a private route, our guide to where to get Wegovy in the UK explains what legitimate access looks like. If you would like a clinical view on whether semaglutide is suitable for your situation, speak to our prescribers through a free consultation, a GPhC-registered Independent Prescriber reviews every submission.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.